Professor Michael Hofman is a nuclear medicine physician at the Peter MacCallum Cancer Centre in Melbourne, Australia's only public hospital dedicated to cancer treatment, research and education. He has a co-appointment at the University of Melbourne and previously completed a fellowship at Guy's & St Thomas' hospital in London. Professor Hofman’s is the director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at Peter Mac. His research is focussed on improving outcomes for men with prostate cancer and he is engaged in pre-clinical, and phase 1 to 3 research. He has led several landmark clinical trials of PSMA imaging and therapy including the ProPSMA Study which has established PSMA PET/CT as a replacement for standard CT and bone scanning, and the TheraP study comparing Lu-177-PSMA to cabazitaxel chemotherapy. He has authored or co-authored over 160 peer-reviewed articles and is a scientific member of the Australasian Radiopharmaceutical Trials Network (ARTnet), Vice-Chairperson of the Oncology Scientific Program for the Society of Nuclear Medicine and Molecular Imaging (SNM) and Board Member of the SNMMI Theranostic Center of Excellence. In these roles, he aims to progress the field through clinical trial development and execution. He is an editor for several international journals including the Journal of Nuclear Medicine.